|
Inmatics Biotechnologies GmbH (IMTXW) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
immatics biotechnologies GmbH (IMTXW) Bundle
¡Simplifique la valoración de Biotecnologías de Inmatics GmbH (IMTXW) con esta calculadora DCF personalizable! Con Biotecnologías de Inmatics Real GmbH (IMTXW) Financials y entradas de pronóstico ajustables, puede probar escenarios y descubrir las biotecnologías inmaticales GmbH (IMTXW) Valor razonable en minutos.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.1 | 32.4 | 36.1 | 179.4 | 56.0 | 71.7 | 91.8 | 117.4 | 150.3 | 192.3 |
| Revenue Growth, % | 0 | 69.4 | 11.23 | 397.17 | -68.76 | 27.97 | 27.97 | 27.97 | 27.97 | 27.97 |
| EBITDA | -30.3 | -66.9 | -86.7 | 51.9 | -92.3 | -53.2 | -68.1 | -87.1 | -111.5 | -142.7 |
| EBITDA, % | -158.03 | -206.19 | -240.37 | 28.95 | -164.69 | -74.21 | -74.21 | -74.21 | -74.21 | -74.21 |
| Depreciation | 4.0 | 4.3 | 5.7 | 7.1 | 7.5 | 9.6 | 12.3 | 15.8 | 20.2 | 25.8 |
| Depreciation, % | 20.85 | 13.19 | 15.73 | 3.96 | 13.4 | 13.43 | 13.43 | 13.43 | 13.43 | 13.43 |
| EBIT | -34.2 | -71.2 | -92.4 | 44.8 | -99.8 | -53.8 | -68.8 | -88.1 | -112.7 | -144.2 |
| EBIT, % | -178.88 | -219.38 | -256.11 | 25 | -178.09 | -75 | -75 | -75 | -75 | -75 |
| Total Cash | 123.9 | 240.7 | 150.6 | 375.9 | 442.0 | 71.7 | 91.8 | 117.4 | 150.3 | 192.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 2.8 | 3.0 | .7 | 2.2 | 4.2 | 5.0 | 6.4 | 8.2 | 10.5 | 13.4 |
| Account Receivables, % | 14.76 | 9.35 | 1.96 | 1.24 | 7.58 | 6.98 | 6.98 | 6.98 | 6.98 | 6.98 |
| Inventories | 1.3 | 3.4 | .0 | .0 | .0 | 2.5 | 3.2 | 4.1 | 5.2 | 6.6 |
| Inventories, % | 6.7 | 10.57 | 0.000002876622 | 0.000000579 | 0.000001851955 | 3.45 | 3.45 | 3.45 | 3.45 | 3.45 |
| Accounts Payable | 5.0 | 2.7 | 3.1 | 4.2 | 8.0 | 8.6 | 11.0 | 14.0 | 18.0 | 23.0 |
| Accounts Payable, % | 26.38 | 8.17 | 8.66 | 2.33 | 14.2 | 11.95 | 11.95 | 11.95 | 11.95 | 11.95 |
| Capital Expenditure | -2.3 | -7.8 | -5.9 | -6.4 | -32.1 | -16.3 | -20.8 | -26.6 | -34.1 | -43.6 |
| Capital Expenditure, % | -12.11 | -24.07 | -16.27 | -3.6 | -57.33 | -22.68 | -22.68 | -22.68 | -22.68 | -22.68 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -33.5 | -71.1 | -94.1 | 40.0 | -99.8 | -52.4 | -67.0 | -85.8 | -109.7 | -140.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -30.8 | -79.4 | -88.1 | 40.2 | -122.7 | -61.6 | -75.2 | -96.2 | -123.1 | -157.6 |
| WACC, % | 7.47 | 7.48 | 7.48 | 7.45 | 7.48 | 7.47 | 7.47 | 7.47 | 7.47 | 7.47 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -402.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -161 | |||||||||
| Terminal Value | -2,939 | |||||||||
| Present Terminal Value | -2,050 | |||||||||
| Enterprise Value | -2,452 | |||||||||
| Net Debt | -211 | |||||||||
| Equity Value | -2,241 | |||||||||
| Diluted Shares Outstanding, MM | 81 | |||||||||
| Equity Value Per Share | -27.83 |
Benefits You Will Receive
- Genuine IMTXW Financial Data: Pre-filled with historical and projected financial information for detailed analysis.
- Completely Customizable Template: Easily adjust key metrics such as revenue growth, WACC, and EBITDA percentage.
- Instant Calculations: Witness real-time updates to IMTXW's intrinsic value as you modify inputs.
- Expert Valuation Tool: Tailored for investors, analysts, and consultants aiming for precise DCF results.
- User-Centric Design: Intuitive layout and straightforward instructions suitable for all skill levels.
Key Features
- Accurate Financial Data: Gain access to reliable historical data and future forecasts for immatics biotechnologies GmbH (IMTXW).
- Adjustable Forecast Parameters: Modify highlighted fields including WACC, growth rates, and profit margins.
- Real-Time Calculations: Automatic adjustments for DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Dashboard: Intuitive charts and summaries that help you easily interpret valuation outcomes.
- Designed for All Skill Levels: A straightforward layout tailored for investors, CFOs, and consultants alike.
Understanding the Process
- Download: Obtain the pre-built Excel file containing financial data for immatics biotechnologies GmbH (IMTXW).
- Customize: Modify your forecasts, including revenue growth, EBITDA %, and WACC to fit your analysis.
- Update Automatically: Intrinsic value and NPV calculations refresh instantly as your inputs change.
- Test Scenarios: Develop various projections and review outcomes side by side without delay.
- Make Decisions: Leverage the valuation outcomes to inform your investment strategy effectively.
Why Choose the Immatics Calculator?
- Save Time: Skip the hassle of building a DCF model from the ground up – it's ready for immediate use.
- Enhance Accuracy: Dependable financial data and formulas minimize errors in your valuations.
- Fully Customizable: Adapt the model to fit your specific assumptions and forecasts.
- Easy to Understand: Intuitive charts and outputs simplify result analysis.
- Trusted by Professionals: Crafted for experts who prioritize precision and functionality.
Who Can Benefit from Our Product?
- Biotechnology Students: Master analytical techniques and apply your knowledge with real-world data.
- Researchers: Utilize advanced models to enhance your academic projects or studies.
- Investors: Validate your hypotheses and evaluate valuation scenarios for immatics biotechnologies GmbH (IMTXW).
- Market Analysts: Optimize your analysis process with a flexible, preconfigured DCF model.
- Entrepreneurs: Understand how major biotech firms, like immatics, approach financial assessments.
Contents of the Template
- Operating and Balance Sheet Data: Pre-filled historical data and forecasts for immatics biotechnologies GmbH (IMTXW), including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), featuring key parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Customizable Discounted Cash Flow models that demonstrate intrinsic value with comprehensive calculations.
- Financial Statements: Pre-loaded financial statements (both annual and quarterly) to facilitate thorough analysis.
- Key Ratios: A compilation of profitability, leverage, and efficiency ratios specific to immatics biotechnologies GmbH (IMTXW).
- Dashboard and Charts: A visual overview of valuation results and assumptions for easy analysis of outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.